AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7119508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 96.6 and 135 million units of human interferon-alpha over 12-15 weeks
Number of subjects: 2
Study 7119508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injections of human interferon-alpha (double blind, placebo-controlled)
Number of subjects: 2
Study 7119508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injections of human interferon-alpha
Number of subjects: 2
Study 31094879 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training
Number of subjects: 40
Study 31094879 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 27622387 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg)
Number of subjects: 12
Study 27622387 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg)
Number of subjects: 12
Study 27622387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26085028 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine/glulisine once daily
Number of subjects: 335
Study 26085028 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart/aspart protamine 30/70 twice daily
Number of subjects: 335
Study 24574939 — intervention group
Group type: EXPERIMENTAL
Intervention: Double J stent insertion
Number of subjects: 53
Study 24574939 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 53
Study 22473780 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 25 ms interval
Number of subjects: 0
Study 22473780 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous transcranial direct current stimulation (TDCS; 2 mA) over the cerebellum
Number of subjects: 0
Study 22473780 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 21.5 ms interval
Number of subjects: 0
Study 19175979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80 to 160 mg/day)
Number of subjects: 139
Study 19175979 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (6 to 10 mg/day)
Number of subjects: 139
Study 19175979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 139
Study 19175979 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 139
Study 17156266 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of D‐amphetamine + physiotherapy
Number of subjects: 25
Study 17156266 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of L‐dopa + physiotherapy
Number of subjects: 25
Study 17156266 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of D‐amphetamine + 50 mg of L‐dopa + physiotherapy
Number of subjects: 25
Study 17156266 — intervention group
Group type: COMPARATOR
Intervention: Placebo + physiotherapy
Number of subjects: 25
Study 15669780 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Management Scale
Number of subjects: 31
Study 15669780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismanagement of insulin
Number of subjects: 31
Study 15669780 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating 3 meals a day, getting insulin every day, and more assistance with meals
Number of subjects: 31
Study 15669780 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/Ethnic Comparison
Number of subjects: 31
Study 12057081 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin re‐uptake inhibitors (SSRIs)
Number of subjects: 0
Study 12057081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9336420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) + Methotrexate (MTX) for 48 weeks (group 1)
Number of subjects: 92
Study 9336420 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CSA) + Methotrexate (MTX) for 24 weeks (group 2)
Number of subjects: 92
Study 16350565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 317
Study 16350565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 317
Study 16350565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 3542323 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg sustained‐release furosemide preparation (FR)
Number of subjects: 12
Study 3542323 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg standard furosemide tablet (F)
Number of subjects: 12
Study 3542323 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 12
Study 29724115 — intervention group
Group type: COMPARATOR
Intervention: Virtual control group created using an algorithm based on integrated data from RCTs.
Number of subjects: 0
Study 29724115 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group from two archived randomized control trials (RCTs) assessing intentions, normative beliefs, values, and substance use.
Number of subjects: 0
Study 27855660 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 mcg/kg (Group F)
Number of subjects: 64
Study 27855660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg/kg (Group O)
Number of subjects: 64
Study 25164220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination therapy (iloprost: 10 µg/inhalation, 6 times per day for 6 months, then add oral tadalafil (5 mg/d) till 12 months, n = 32)
Number of subjects: 72
Study 25164220 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront combination therapy (iloprost: 10 µg/inhalation, 6 times per day combined with oral tadalafil (5 mg) for 12 months, n = 36)
Number of subjects: 72
Study 22613154 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP)
Number of subjects: 22
Study 22613154 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) + Ketorolac
Number of subjects: 22
Study 20051917 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM arthroplasty
Number of subjects: 251
Study 20051917 — intervention group
Group type: COMPARATOR
Intervention: ACDF (control)
Number of subjects: 251
Study 18544952 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a monotherapy
Number of subjects: 63
Study 15780524 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5mg/day for 48 weeks
Number of subjects: 116
Study 15780524 — intervention group
Group type: COMPARATOR
Intervention: Control group (free-treatment)
Number of subjects: 116
Study 12353080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 12353080 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C69931MX
Number of subjects: 0
Study 12353080 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 10333139 — intervention group
Group type: EXPERIMENTAL
Intervention: HBY 097 (non-nucleoside inhibitor of HIV-1 reverse transcriptase)
Number of subjects: 2
Study 10333139 — intervention group
Group type: EXPERIMENTAL
Intervention: HBY 097
Number of subjects: 2
Study 10333139 — intervention group
Group type: COMPARATOR
Intervention: In vitro selection studies
Number of subjects: 2
Study 9374447 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (20 ng/kg/min)
Number of subjects: 14
Study 9374447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1909603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine 10 mg b.i.d.
Number of subjects: 30
Study 1909603 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine 5 mg b.i.d. (controlled release)
Number of subjects: 30
Study 1909603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 1909603 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither treatment
Number of subjects: 30
Study 1909603 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine
Number of subjects: 30
Study 1909603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine
Number of subjects: 30
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative use of special elastic bandages and oxyphenbutazone
Number of subjects: 0
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: New traction treatment called auto‐traction
Number of subjects: 0
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: New mechanical device for tibial osteotomy
Number of subjects: 0
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: Deyerle's technique for intracapsular hip fractures
Number of subjects: 0
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: New radiologic method for determining stability of tibial fractures
Number of subjects: 0
Study 6238741 — intervention group
Group type: COMPARATOR
Intervention: Three to four weeks of immobilization for shoulder joint dislocations
Number of subjects: 0
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of Colles' fracture with electromagnetic fields
Number of subjects: 0
Study 6238741 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic percutaneous meniscectomies
Number of subjects: 0
Study 31215805 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.5 meq·kg body wt‐1·day‐1)
Number of subjects: 120
Study 31215805 — intervention group
Group type: COMPARATOR
Intervention: NaCl (0.5 meq·kg body wt‐1·day‐1)
Number of subjects: 120
Study 31215805 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 120
Study 30498836 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month interdisciplinary intervention based on physical exercise, Mediterranean diet advice, assessment of inadequate prescribing in polypharmacy patients and social assessment
Number of subjects: 200
Study 30498836 — intervention group
Group type: COMPARATOR
Intervention: Standard primary healthcare treatment
Number of subjects: 200
Study 27824811 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg b.i.d. (capsules)
Number of subjects: 265
Study 27824811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 25282564 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer applied daily during the first 32 weeks of life
Number of subjects: 59
Study 25282564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no moisturizer)
Number of subjects: 59
Study 25282564 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer
Number of subjects: 59
Study 25282564 — intervention group
Group type: COMPARATOR
Intervention: Infants with AD/eczema
Number of subjects: 59
Study 21803547 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid alone
Number of subjects: 81
Study 21803547 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroid/bronchodilator therapy (continuing treatment)
Number of subjects: 81
Study 20212319 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted logrank test for cause-specific mortality
Number of subjects: 41224
Study 20212319 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality analysis
Number of subjects: 41224
Study 20212319 — intervention group
Group type: COMPARATOR
Intervention: Naive cause-specific logrank test
Number of subjects: 41224
Study 17697829 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate/hydralazine (ID/H) taken for an additional 209 ± 116 days
Number of subjects: 198
Study 17697829 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate/hydralazine (ID/H)
Number of subjects: 198
Study 16390805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 20 mg/kg IV
Number of subjects: 45
Study 16390805 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 16390805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 45
Study 12566747 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood collection before placental detachment (group A)
Number of subjects: 47
Study 12566747 — intervention group
Group type: COMPARATOR
Intervention: Umbilical cord blood collection after placental delivery (group B)
Number of subjects: 47
Study 9585793 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml double-strength, three times a day for 2 days)
Number of subjects: 10
Study 7658286 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation, large doses (exact dosage not specified)
Number of subjects: 0
Study 2670423 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg norethindrone and 0.035 mg ethinyl estradiol (NET + EE)
Number of subjects: 0
Study 2670423 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg norgestrel and 0.03 mg ethinyl estradiol (Ng + EE)
Number of subjects: 0
Study 2670423 — intervention group
Group type: EXPERIMENTAL
Intervention: NET + EE
Number of subjects: 0
Study 1138664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium Tosylate
Number of subjects: 31
Study 1138664 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 31
Study 31345107 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d, n=31)
Number of subjects: 93
Study 31345107 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (5 mg/d, n=31)
Number of subjects: 93
Study 31345107 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (n=31)
Number of subjects: 93
Study 31092660 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mental health intervention delivered by lay health workers in primary care services
Number of subjects: 0
Study 31092660 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-sharing approaches to integrating services for common mental disorders with HIV and diabetes primary care services
Number of subjects: 0
Study 31092660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost utility analyses
Number of subjects: 0
Study 31092660 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider and patient cost per patient year for each study arm and chronic disease
Number of subjects: 0
Study 28430522 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic lighting
Number of subjects: 0
Study 28430522 — intervention group
Group type: COMPARATOR
Intervention: Standard lighting (Control)
Number of subjects: 0
Study 25746727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (containing vitamin B1, B2, niacin, B6, B12, folic acid, C, carnitine, coenzyme Q10, naïve galacto-oligosaccharide, and zinc) for 12 weeks after each dialysis session.
Number of subjects: 202
Study 25746727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation for 12 weeks.
Number of subjects: 202
Study 25746727 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks after each dialysis session.
Number of subjects: 202
Study 23176986 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil 5.0 μg
Number of subjects: 96
Study 23176986 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 100 μg
Number of subjects: 96
Study 23176986 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine 75 μg
Number of subjects: 96
Study 23176986 — intervention group
Group type: COMPARATOR
Intervention: no adjuvant (Group I)
Number of subjects: 96
Study 19948385 — intervention group
Group type: EXPERIMENTAL
Intervention: MF11RCE (80mg red clover isoflavones)
Number of subjects: 109
Study 19948385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 18720713 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant coaxil during perioperative period (6 weeks)
Number of subjects: 61
Study 18720713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coaxil treatment)
Number of subjects: 61
Study 16505759 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated large volume paracentesis plus intravenous albumin (group 1)
Number of subjects: 20
Study 16505759 — intervention group
Group type: COMPARATOR
Intervention: Combination of clonidine (0.075 mg twice daily) and spironolactone (200 to 400 mg daily) (group 2)
Number of subjects: 20
Study 16505759 — intervention group
Group type: COMPARATOR
Intervention: Combination of clonidine and spironolactone (group 2)
Number of subjects: 20
Study 12450445 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly fructosamine testing (Group 1)
Number of subjects: 60
Study 12450445 — intervention group
Group type: COMPARATOR
Intervention: Usual care of daily glucose (Group 2)
Number of subjects: 60
Study 10352786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2 micrograms/kg per min)
Number of subjects: 20
Study 10352786 — intervention group
Group type: COMPARATOR
Intervention: Dopexamine (0.5 microgram/kg per min)
Number of subjects: 20
Study 10352786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20
Study 10352786 — intervention group
Group type: COMPARATOR
Intervention: Dopexamine
Number of subjects: 20
Study 7795502 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (80 mg/100 ml)
Number of subjects: 90
Study 7795502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alcohol (40 mg/100 ml)
Number of subjects: 90
Study 7795502 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting alcohol with high dose alcohol
Number of subjects: 90
Study 7795502 — intervention group
Group type: COMPARATOR
Intervention: Placebo with expectancy of alcohol
Number of subjects: 90
Study 1646259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (260 mmol NaCl/day)
Number of subjects: 23
Study 1646259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (20 mmol NaCl/day)
Number of subjects: 23
Study 7025168 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg body weight as a single dose
Number of subjects: 138
Study 7025168 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg as a single dose
Number of subjects: 138
Study 7025168 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg, twice a day at a 6-hour interval
Number of subjects: 138
Study 7025168 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages
Number of subjects: 138
Study 28881147 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling
Number of subjects: 11
Study 28881147 — intervention group
Group type: COMPARATOR
Intervention: Passive leg cycling
Number of subjects: 11
Study 26243373 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis therapy plus Silybum marianum capsule
Number of subjects: 370
Study 26243373 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculosis therapy plus vitamin C tablet
Number of subjects: 370
Study 24576517 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended administration of oral betrixaban (35‐42 days)
Number of subjects: 1000
Study 24576517 — intervention group
Group type: COMPARATOR
Intervention: Standard short course of prophylaxis with subcutaneous enoxaparin (10 ± 4 days followed by placebo)
Number of subjects: 1000
Study 22510506 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiji Decoction for soothing the liver combined with psychotherapy and chemotherapy
Number of subjects: 118
Study 22510506 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 118
Study 20731638 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 20
Study 20731638 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 18400357 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RG)
Number of subjects: 80
Study 18400357 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study 16402568 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (ALLO, n = 31)
Number of subjects: 54
Study 16402568 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITRA, n = 23)
Number of subjects: 54
Study 16402568 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 12606175 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural interventions alone (group A)
Number of subjects: 0
Study 12606175 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural and STI interventions (group B)
Number of subjects: 0
Study 12606175 — intervention group
Group type: COMPARATOR
Intervention: Routine government health services and community development activities (group C)
Number of subjects: 0
Study 10575655 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomoxir (ETO) 75 mg
Number of subjects: 28
Study 10575655 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomoxir (ETO) 150 mg
Number of subjects: 28
Study 10575655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8688226 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent external radiation therapy (70 Gy/39 fractions/8 weeks) and chemotherapy with cisplatin (50 mg/m2 in short infusion, D1, D15, D29, D43) and fluorouracil (5 mg/kg, intra-muscular, every Monday, Wednesday and Friday)
Number of subjects: 67
Study 8688226 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone with the same modalities
Number of subjects: 67
Study 8688226 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (non responders to induction chemotherapy)
Number of subjects: 67
Study 8688226 — intervention group
Group type: COMPARATOR
Intervention: Control group (non responders to induction chemotherapy)
Number of subjects: 67
Study 8688226 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (responders to induction chemotherapy)
Number of subjects: 67
Study 8688226 — intervention group
Group type: COMPARATOR
Intervention: Control group (responders to induction chemotherapy)
Number of subjects: 67
Study 8688226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 1770421 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Dentifrice with 0.075% sanguinaria extract and 2.0% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Number of subjects: 120
Study 1770421 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Dentifrice with 0.8% sodium monofluorophosphate, 0.075% sanguinaria extract, and 0.05% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Number of subjects: 120
Study 1770421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 2 and Group 4: identical products without sanguinaria extract or zinc chloride).
Number of subjects: 120
Study 7052184 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion group
Number of subjects: 38